Form 4: Eton Pharmaceuticals Executive Reports Stock Transaction
Insider Transaction (Form 4)
David Krempa, Chief Business Officer of Eton Pharmaceuticals, Inc., reported multiple transactions in common stock on July 12, 2026.
Summary
- Option exercise/conversion: acquired 10,000 Common Stock on July 12, 2026; holds 37,025 after (Direct).
- Option exercise/conversion: disposed of 10,000 Restricted Stock Units on July 12, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
David Krempa — Officer (Chief Business Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-12 | Option exercise/conversion | Common Stock | 10,000 | — | — | 37,025 |
| 2026-07-12 | Option exercise/conversion | Restricted Stock Units | 10,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-12 | Option exercise/conversion (10,000 shares) |
| 2026-07-12 | Option exercise/conversion (10,000 shares) |
Keywords
insider transaction, Form 4, ETON, Eton Pharmaceuticals, Inc., neutral, David Krempa
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.